- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- News News
- Join Join
Americans for Safe Access Applauds Action and Calls Upon Congress to Take Note
WASHINGTON, DC — In a letter dated January 26th, Americans for Safe Access (ASA), a national nonprofit organization dedicated to ensuring safe and legal access to medical cannabis for therapeutic use and research, learned that the Drug Enforcement Administration (DEA) denied their Information Quality Act (IQA) petition requesting the correction of misinformation disseminated on the DEA website on the health effects of medical cannabis, originally filed more than a year ago. However, the letter also pointed out that, through a “regular review process,” the DEA had removed certain documents and updated much of the information on the DEA website that ASA’s IQA petition addressed.
The IQA petition process is a mechanism designed to ensure the “quality, objectivity, utility, and integrity of information” presented by the Government. For years, the DEA published scientifically incomplete and inaccurate information about the health effects of medical cannabis, which directly influenced the action —and inaction— of Congress. ASA noted that the DEA directly contradicted much of this misinformation in recent public statements, and used the DEA’s own words confirming scientific facts about medical cannabis in the IQA petition to ask it to change or take down the incorrect information. ASA strongly asserted that the information called for correction so that Congress could have access to the appropriate tools to make informed decisions about public health.
Elected officials rely on the DEA to provide fact-based information about medical cannabis to inform policy making decisions, such as whether or not to support the CJS Medical Marijuana Amendment, or the CARERS Act of 2017 (S.1764 and H.R. 2920). The DEA’s removal of this inaccurate information is a significant success because it means that politicians can no longer use the misinformation about the gateway drug hypothesis and cannabis causing irreversible cognitive decline in adults, psychosis, or lung cancer as a basis for their lack of support on medical cannabis policy.While waiting for a response to the IQA petition, ASA highlighted the public interest by launching an online petition calling on the DEA to correct the misinformation. Shortly after ASA’s petition reached over 100,000 signatures, the DEA removed the document “Dangers and Consequences of Marijuana,” which contained 23 of the 25 factual inaccuracies that ASA pointed out in their petition, from their website. Through their “regular review process”, in January 2017, they also made several updates to the document “Drugs of Abuse,” which included the other two inaccuracies.
“Medical cannabis advocates have consistently fought for the opportunity to debate medical policy based on facts. For the last two decades, everyone from politicians to medical professionals have cited the mistruths from the DEA as a reason to keep medical cannabis from patients,” said Steph Sherer, Executive Director of ASA. “This is a giant win for medical cannabis patients, advocates and political allies. We can only hope that Attorney General Sessions is paying attention to the DEA’s “regular review process” findings.”
“At the end of the day, it does not matter why the DEA decided to update their materials. The key is that this influential organization that Congress relies on to make policy decisions is no longer disseminating mistruths about the gateway theory, and cannabis’ influence on psychosis, cognitive decline, and long term brain damage,” stated Mark Wine, a Southern California based partner in the international law firm Orrick, whose team filed the petition for ASA. “We will continue to work with patient advocates to make sure their voices are heard and that only scientifically accurate information is made available to those that are making political decisions.”
# # # # #